Clin2
NCT07568665Possibly a fitRecruiting

Skin Changes in Atopic Dermatitis Patients on Tralokinumab

Atopic Dermatitis (AD)Atopic Dermatitis (Eczema)

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This study uses a special microscope to take close-up pictures of your skin before and after starting tralokinumab, a biologic medication for moderate-to-severe eczema (atopic dermatitis). Researchers want to understand how this treatment changes your skin at a microscopic level.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
15 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be 18 years or older
  • You have moderate-to-severe atopic dermatitis (eczema) that your doctor believes needs tralokinumab treatment
  • You are enrolled in a French social security or health insurance scheme
  • You can understand the study and freely agree to participate by signing a consent form
  • You do not have uncontrolled chronic diseases requiring frequent steroid treatment
  • You do not have other serious health conditions that would interfere with the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07730788Recruiting
Skin imaging study in eczema patients receiving nemolizumab

This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.

Romans-sur-Isère, Drôme
NCT06837454Recruiting
Study of eczema patients on systemic therapy

This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.

Aix-en-Provence
NCT07444801Recruiting
Tralokinumab for eczema with genital symptoms

This trial tests if tralokinumab, a drug already approved for moderate-to-severe eczema, helps people who also have eczema in the genital area. It aims to understand how well the drug works for this specific symptom.

Augsburg, München
NCT05938478Recruiting
Pregnancy registry for outcomes after tralokinumab exposure

This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.

La Jolla, California
NCT06311682Recruiting· Phase 3
Testing a new shot plus steroid cream for children with eczema

This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.

Birmingham, Alabama
NCT01631617Recruiting· Phase 2
Atopic dermatitis treatments and how they affect skin

This Phase 2 study tests different treatments for atopic dermatitis (eczema) by looking at changes in skin health. It may help people find safer, more effective ways to control moderate to severe eczema and related skin infections.

Bethesda, Maryland

Hear when a new Atopic Dermatitis (Eczema) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.